Pfizer stock snapshot and recent performance

Pfizer (PFE) is back in focus for investors, with the stock closing at US$25.33 and showing mixed performance, including a gain over the past year alongside declines over the past month and past 3 months.

Recent trading has been weak, with the share price return down 6.84% over the past 30 days and 8.16% over 90 days. The 1 year total shareholder return is 18.70%, which suggests earlier momentum has cooled as investors reassess growth prospects and risks around Pfizer.

If you are comparing Pfizer with other healthcare opportunities, it can be useful to see what else the market is pricing into companies using AI in medicine through 32 healthcare AI stocks

With Pfizer valued at around US$146.8b, trading at US$25.33 per share and showing an intrinsic discount estimate of about 58%, the key question is whether this signals a genuine opportunity or whether markets are already pricing in future growth.

Most Popular Narrative: 17.3% Undervalued

Pfizer's narrative fair value of $30.62 sits above the last close at $25.33. In this widely followed view, the stock is framed as undervalued.

I think that Pfizer has a strong pipeline. The acquisition of Seagen added many new oncology products that are expected to grow by 14%, partially offsetting the decline in sales of the COVID-19 vaccines. This could keep revenue flat, with the possibility of low to mid single-digit growth in an optimistic scenario. Also, I think they will continue to release many new products that are already in phase 3 of research. If they are able to do this, maintain a 70% operational margin, increase profitability (by cutting costs, expanding margins, etc.) and pay down debt, in the long term I see the potential for good annual returns (low double digits) from current stock price levels.

Want to see how oncology growth, margin targets and debt reduction come together in this fair value story? The narrative outlines the cash flow path behind that $30.62 figure and the expectations reflected in future earnings power.

Result: Fair Value of $30.62 (UNDERVALUED)

However, this story can unravel if oncology growth underdelivers, or if high debt and potential dividend pressure weigh more heavily on investor confidence.

Another View: What P/E Says About Pfizer

If you step away from cash flow models and just look at the P/E, Pfizer trades at 19.3x earnings, above the US pharmaceuticals average of 14.8x but below the 21x peer average and the 20.3x fair ratio. That mix points to valuation risk as well as potential upside if sentiment shifts.

Before leaning too hard on any single earnings multiple, it helps to see how those ratios connect to actual business quality, debt and profit trends, not just the current share price chart. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of caution and optimism feels familiar, use it as a prompt to review the numbers yourself and move efficiently toward your own view with 1 key reward and 4 important warning signs

Looking for more investment ideas?

If Pfizer has sharpened your thinking, do not stop here. Broaden your watchlist with focused stock ideas filtered by quality, value and resilience using the Simply Wall Street Screener.

• Target potential mispricings by scanning for quality businesses trading below their estimated worth through 50 high quality undervalued stocks
• Prioritise capital preservation and smoother portfolio swings with companies screened for resilience and lower risk profiles using 66 resilient stocks with low risk scores
• Hunt for less crowded opportunities by filtering for strong fundamentals in companies the market may be overlooking through screener containing 22 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.